Bone deposition, bone resorption, and osteosarcoma

Journal of Orthopaedic Research

Volumn 28, Issue 9, 2010, Pages 1142-1148

  Toledo, Sílvia Regina Caminada ^a   Oliveira, Indhira Dias ^a   Okamoto, Oswaldo Keith ^a   Zago, Marco Antonio ^b   Alves, Maria Teresa De Seixas ^a   Garcia Filho, Reynaldo Jesus ^a   Macedo, Carla Renata Pacheco Donado ^a   Petrilli, Antonio Sergio ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

BMP7; Bone remodeling; COL11A2; Osteosarcoma

Indexed keywords

ACID PHOSPHATASE; CARBOPLATIN; CISPLATIN; COLLAGEN TYPE 11; COLONY STIMULATING FACTOR 1; DOXORUBICIN; IFOSFAMIDE; MESNA; MESSENGER RNA; OSTEOGENIC PROTEIN 1; PROTEIN TYROSINE PHOSPHATASE; RAZOXANE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; COL11A2 PROTEIN, HUMAN; COLONY STIMULATING FACTOR RECEPTOR; ISOENZYME; PTPRZ1 PROTEIN, HUMAN; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; TARTRATE-RESISTANT ACID PHOSPHATASE;

ARTICLE; BONE REMODELING; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL FEATURE; EVENT FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; OSTEOLYSIS; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; ADOLESCENT; ADULT; BIOPSY; BONE MINERALIZATION; BONE TUMOR; CHILD; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; SURVIVAL;

ACID PHOSPHATASE; ADOLESCENT; BIOPSY; BONE MORPHOGENETIC PROTEIN 7; BONE NEOPLASMS; BONE RESORPTION; CALCIFICATION, PHYSIOLOGIC; CHILD; COLLAGEN TYPE XI; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; MALE; OSTEOSARCOMA; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 5; RNA, MESSENGER; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 77955913132     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21120     Document Type: Article

References (43)

1. Katagiri T, Nakahashi N. 2002. Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis 8:147-159.
2. Cohen MM Jr. 2006. The new bone biology: pathologic, molecular, and clinical correlates. Am J Med Genet A 140A: 2646-2706.
3. Clohisy DR, Perkins SL, Ramnaraine ML. 2000. Review of cellular mechanisms of tumor osteolysis. Clin Orthop Relat Res 373:104-114.
4. Meyers PA, Gorlick R. 1997. Osteosarcoma. Pediatr Clin North Am 44:973-989.
5. Bielack SS, Bielack-Kempf B, Delling G, et al. 2002. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on Neoadjvant Cooperative Osteosarcoma Study Group Protocols. J Clin Oncol 20:776-790.
6. Bacci G, Bertoni F, Longhi A, et al. 2003. Neoadjvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer 97:3068-3075.
7. Petrilli AS, de Camargo B, Filho VO, et al. 2006. Brazilian Osteosarcoma Treatment Group Studies III and IV Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol 24:1161-1168.
8. Oliveira ID, Petrilli AS, Tavela MH, et al. 2007. TNF-alpha, TNF-beta, IL-6, IL-10, PECAM-1 and the MPO inflammatory gene polymorphisms in osteosarcoma. J Pediatr Hematol Oncol 29:293-297.
9. Lamoureux F, Trichet V, Chipoy C, et al. 2007. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther 7(2):169-181. Review.
10. Chirgwin JM, Guise TA. 2000. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 10(2):159-178. Review.
11. Guise TA, Mohammad KS. 2004. Endothelins in bone cancer metastases. Cancer Treat Res 118:197-212. Review.
12. Angel NZ, Walsh N, Forwood MR, et al. 2000. Transgenic mice overexpressing tartrate-resistant acid phosphatase exhibit an increased rate of bone turnover. Bone Miner Res 15:103-110.
13. Walsh NC, Cahill M, Carninci P, et al. 2003. Multiple tissue-specific promoters control expression of the murine tartrate-resistant acid phosphatase gene. Gene 307:111-123.
14. Oddie GW, Schenk G, Angel NZ, et al. 2000. Structure, function, and regulation of tartrate-resistant acid phosphatase. Bone 27:575-584.
15. Logar DB, Komadina R, Prezelj J, et al. 2007. Expression of bone resorption genes in osteoarthritis and in osteoporosis. J Bone Miner Metab 25(4):219-225.
16. Hollberg K, Nordahl J, Hultenby K, et al. 2005. Polarization and secretion of cathepsin K precede tartarate-resistant acid phosphatase secretion to the ruffled border area during the activation of matrix-resorbing clasts. J Bone Miner Metab 23:441-449.
17. Teitelbaum SL, Ross FP. 2003. Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638-649.
18. Ross FP, Teitelbaum SL. 2005. avb3 and macrophage colony stimulating factor: partners in osteoclast biology. Immunol Rev 208:88-105.
19. Kodama H, Nose M, Niida S, et al. 1991. Essential role of macrophage colony stimulating factor in the osteoclast differentiation supported by stromal cells. J Exp Med 173:1291-1294.
20. Haydon RC, Luu HH, He TC. 2007. Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis. Clin Orthop Relat Res 454:237-246.
21. Hogan BL. 1996. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev 10:1580-1594.
22. De Biase P, Capanna R. 2005. Clinical applications of BMPs. Injury 36:S43-S46.
23. Ducy P, Karsenty G. 2000. The family of bone morphogenetic proteins. Kidney Int 57:2207-2214.
24. Mehdi R, Shimizu T, Yoshimura Y, et al. 2000. Expression of bone morphogenetic protein and its receptors in osteosarcoma and malignant fibrous histiocytoma. Jpn J Clin Oncol 30(6):272-275. (Pubitemid 30628102)
25. Gobbi G, Sangiorgi L, Lenzi L, et al. 2002. Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells. Int J Oncol 20:143-147.
26. Yoshikawa H, Nakase T, Myoui A, et al. 2004. Bone morphogenetic proteins in bone tumors. J Orthop Sci 9:334-340.
27. Chandar N, Swindle J, Szajkovics A, et al. 2005. Relationship of bone morphogenetic protein expression during osteoblast differentiation to wild type p53. J Orthop Res 23:1345-1353. (Pubitemid 41554667)
28. Sulzbacher I, Birner P, Trieb K, et al. 2002. The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter. J Clin Pathol 55:381-385.
29. Guo W, Gorlick R, Ladanyi M, et al. 1999. Expression of bone morphogenetic proteins and receptors in sarcomas. Clin Orthop Relat Res 365:175-183.
30. Okazaki K, Sandell LJ. 2004. Extracellular matrix gene regulation. Clin Orthop Relat Res 427S:S123-S128.
31. Goto T, Matsui Y, Fernandes RJ, et al. 2006. Sp1 family of transcription factors regulates the human alpha2 (XI) collagen gene (COL11A2) in Saos-2 osteoblastic cells. J Bone Miner Res 21(5):661-673.
32. Matsui Y, Kimura T, Tsumaki N, et al. 1998. Splicing patterns of type XI collagen transcripts act as molecular markers for osteochondrogenic tumors. Cancer Lett 124(2):143-148.
33. Schiller KR, Mauro LJ. 2005. Tyrosine phosphatases as regulators of skeletal development and metabolism. J Cell Biochem 96:262-277.
34. Hunter T. 1998. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. Philos Trans R Soc Lond B Biol Sci 353:583-605.
35. Tonks NK. 2006. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 7:833-846.
36. Gorlick R. 2002. Osteosarcoma: clinical practice and the expanding role of biology. J Musculoskel Neuron Interact 2:549-551.
37. Spangler JG. 2008. Bone biology and physiology: implications for novel osteoblastic osteosarcoma treatments? Med Hypotheses 70(2):281-286.
38. Sugimoto M, Kimura T, Tsumaki N, et al. 1998. Differential in situ expression of alpha2(XI) collagen mRNA isoforms in the developing mouse. Cell Tissue Res 292(2):325-332.
39. Urabe K, Jingushi S, Ikenoue T, et al. 2001. Immature osteoblastic cells express the pro-alpha2(XI) collagen gene during bone formation in vitro and in vivo. J Orthop Res 19(6):1013-1020.
40. Maeda S, Ishidou Y, Koga H, et al. 2001. Functional impact of human collagen alpha2(XI) gene polymorphism in pathogenesis of ossification of the posterior longitudinal ligament of the spine. J Bone Miner Res 16(5):948-957. (Pubitemid 32332306)
41. Shay JW, Wright WE. 1996. Telomerase activity in human cancer. Curr Opin Oncol 8(1):66-71. Review.
42. Cassar L, Li H, Pinto AR, et al. 2008. Bone morphogenetic protein-7 inhibits telomerase activity, telomere maintenance, and cervical tumor growth. Cancer Res 68(22):9157-9166.
43. Cassar L, Nicholls C, Pinto AR, et al. 2009. Bone morphogenetic protein-7 induces telomerase inhibition, telomere shortening, breast cancer cell senescence, and death via Smad3. FASEB J 23(6):1880-1892.